PRQR N Stock Overview
A biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
ProQR Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.00 |
| 52 Week High | US$36.00 |
| 52 Week Low | US$36.00 |
| Beta | 0.22 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -75.34% |
| 5 Year Change | n/a |
| Change since IPO | -68.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| PRQR N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how PRQR N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how PRQR N performed against the MX Market.
Price Volatility
| PRQR N volatility | |
|---|---|
| PRQR N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: PRQR N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine PRQR N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 157 | Daniel de Boer | www.proqr.com |
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets.
ProQR Therapeutics N.V. Fundamentals Summary
| PRQR N fundamental statistics | |
|---|---|
| Market cap | Mex$7.20b |
| Earnings (TTM) | -Mex$511.68m |
| Revenue (TTM) | Mex$392.96m |
18.3x
P/S Ratio-14.1x
P/E RatioIs PRQR N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRQR N income statement (TTM) | |
|---|---|
| Revenue | €18.39m |
| Cost of Revenue | €0 |
| Gross Profit | €18.39m |
| Other Expenses | €42.33m |
| Earnings | -€23.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 100.00% |
| Net Profit Margin | -130.21% |
| Debt/Equity Ratio | 18.1% |
How did PRQR N perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/10 02:59 |
| End of Day Share Price | 2024/09/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ProQR Therapeutics N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | B. Riley Wealth |
| Eliana Merle | Cantor Fitzgerald & Co. |
| Steven Seedhouse | CGS International |